Episode Details

Australia’s drug approval system is leaving patients behind—just 25% of new global treatments hit the PBS, leaving 18 life-changing therapies, including breakthroughs for schizophrenia, narcolepsy, and prostate cancer, out of reach. Pharma giants cite a sluggish, costly process and low reimbursement as reasons to skip the Aussie market. For Tina Powney, a rare lung disease patient, a new US/EU-approved drug could mean ditching her 24/7 IV system for simple weekly injections. Health officials are reviewing 50 proposals to speed approvals—but patients are waiting, and time is running out.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4cc6080491394bf6